Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

335.26 22.24 +7.10%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

5 4 5 8
ROE
(4.35%) (6.01%) (7.69%) 1.21%
ROA
(1.97%) (2.41%) (3.16%) 0.54%
ROIC
0.31% 0.81% 1.07% 1.81%
Return on Tangible Assets
(7.28%) (9.69%) (12.62%) 2.07%
Average Days of Receivables
64.44 63.47 64.96 67.49
Free Cash Flow per Share
10.46 7.99 7.72 8.36
Free Cash Flow
518.49 391.29 370.61 399.63
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026